Currently, in patients with stage IB to IIIA epidermal growth factor receptor (EGFR) mutation-positive resected NSCLC, osimertinib demonstrated significantly longer disease-free survival when compared with placebo [11]. Here, EGFR is linked to non-small cell lung carcinoma.